Menu Search
Equities

Biogaia AB

BIOG B:STO

Biogaia AB

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (SEK)106.10
  • Today's Change1.40 / 1.34%
  • Shares traded11.00k
  • 1 Year change-2.21%
  • Beta0.6242
Data delayed at least 15 minutes, as of Nov 22 2024 11:01 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy0
Outperform2
Hold0
Sell0
Strong Sell0

Share price forecast in SEK

The 2 analysts offering 12 month price targets for BioGaia AB have a median target of 165.00, with a high estimate of 180.00 and a low estimate of 150.00. The median estimate represents a 57.59% increase from the last price of 104.70.
High71.9%180.00
Med57.6%165.00
Low43.3%150.00

Dividends

In 2023, Biogaia AB reported a dividend of 6.90 SEK, which represents a 137.93% increase over last year. The analyst covering the company expects dividends of 1.90 SEK for the upcoming fiscal year, a decrease of 72.46%.
Div growth (TTM)137.93%
More ▼

Earnings history & estimates in SEK

On Oct 22, 2024, BioGaia AB reported 3rd quarter 2024 earnings of 0.36 per share.
The next earnings announcement is expected on Feb 12, 2025.
Average growth rate-7.36%
BioGaia AB reported annual 2023 earnings of 3.62 per share on Feb 07, 2024.
Average growth rate+19.46%
More ▼

Revenue history & estimates in SEK

BioGaia AB (publ) had 3rd quarter 2024 revenues of 303.97m. This missed the 324.90m consensus estimate of the 2 analysts following the company. This was 16.91% below the prior year's 3rd quarter results.
Average growth rate+0.23%
BioGaia AB (publ) had revenues for the full year 2023 of 1.30bn. This was 17.44% above the prior year's results.
Average growth rate+15.09%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.